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It has recently become clear that CDH13 (H-cadherin, T-cadherin) expression is frequently silenced by aberrant methylation in
colorectal cancers and adenomas. In this study, we investigated the methylation status of CDH13 gene and detected aberrant
promoter methylation in 27 of 84 (32%) colorectal cancers. We then correlated the results with the clinicopathological features of
affected patients. We found a significant difference in histology (P¼0.0053) when we compared the CDH13 methylation of poorly
differentiated colorectal cancers to that of differentiated ones. This result suggested that poorly differentiated colorectal cancers
specifically exhibited CDH13 methylation, and since CDH13 might be responsible for selective cell recognition and adhesion,
inactivation of CDH13 could lead to the formation of scattered carcinoma cells in these cancers.
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There is now good evidence that a series of genetic alterations in
both dominant oncogenes and tumour suppressor genes are
involved in the pathogenesis of human colorectal cancer.
Activation of oncogenes such as the ras gene, and inactivation of
tumour suppressor genes such as the APC and p53 genes have been
identified in colorectal cancer (Bos et al, 1987; Baker et al, 1990;
Nishisho et al, 1991). In addition, we found that several other
genes are related to the pathogenesis of colorectal cancer (Hibi
et al, 1996; Hibi et al, 1997; Hibi et al, 2002; Yamazaki et al, 2002).
An investigation of genetic changes is important to clarify the
tumorigenic pathway of colorectal cancer (Vogelstein et al, 1988).
Several tumour suppressor genes contain CpG islands in their
promoters, prompting many studies that investigate the role of
methylation in silencing these genes. Many tumour suppressor
genes show evidence of methylation silencing, providing a new
potential pathway for the deactivation of tumour suppressor
genes (Herman et al, 1996). It has recently become clear that
CDH13 (H-cadherin, T-cadherin) expression is frequently silenced
by aberrant methylation in colorectal cancers and adenomas
(Toyooka et al, 2002). CDH13 encodes a protein belonging to the
cadherin family of cell surface glycoproteins responsible for
selective cell recognition and adhesion (Takeichi, 1991). Ubiqui-
tous methylation of CDH13 in colorectal cancers and adenomas
indicated that such methylation occurs at an early stage in the
multistage process of oncogenesis. However, we do not yet know
what roles CDH13 methylation play in colorectal cancers.
In this study, we investigated the methylation status of CDH13 in
84 colorectal cancers that were examined pathologically. We then
correlated the results with the clinicopathological features of
affected patients.
MATERIALS AND METHODS
Sample collection and DNA preparation
A total of 84 primary tumours and corresponding colorectal
epithelial tissues were collected at the Nagoya University School of
Medicine from Japanese colorectal cancer patients who had been
diagnosed histologically. These samples were obtained during
surgery. All tissues were quickly frozen in liquid nitrogen and
stored at  801C until analysis. Tumour and normal tissue samples
were digested overnight by proteinase K, and DNA was prepared
by extraction with phenol. Oral or written informed consent, as
indicated by the institutional review board, was obtained from all
patients. There was no family history about cancers in poorly
differentiated colorectal cancer patients. Tumour sites of six poorly
differentiated colorectal cancers were rectum (three patients),
sigmoid colon (one patient), and cecum (two patients).
Bisulphite modification and methylation-specific PCR
(MSP)
DNA from tumour and normal tissue specimens was subjected
to bisulphite treatment as described previously (Hibi et al, 2001).
The modified DNA was used as a template for MSP. Primer
sequences of CDH13 for amplification were described previously
(Sato et al, 1998). The primers for the unmethylated reaction were:
CDH13UMS (sense), 50-TTGTGGGGTTGTTTTTTGT, and CDH13-
UMAS (antisense), 50-AACTTTTCATTCATACACACA, which am-
plify a 242bp product. The primers for the methylated reaction
were: CDH13MS (sense), 50- TCGCGGGGTTCGTTTTTCGC, and
CDH13MAS (antisense), 50-GACGTTTTCATTCATACACGCG,
which amplify a 243bp product. The PCR amplification of modi-
fied DNA samples consisted of one cycle of 951C for 5min;
33 cycles of 951C for 30s, 601C for 1min, and 721C for 1min for
the unmethylated reaction, or 29 cycles of 951C for 30s, 701C for
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y1min, and 721C for 1min for the methylated reaction; one cycle of
721C for 5min. DNAs from TE1 (oesophageal squamous cell
cancer cell line) and SW1417 (colon cancer cell line) were used as
positive controls for CDH13 amplification of unmethylated and
methylated alleles, respectively. The methylation status of SW1417
cells has been examined previously (Toyooka et al, 2002). Control
reactions without DNA were performed for each set of PCR. A
measure of 10ml of each PCR product was directly loaded onto
nondenaturing 6% polyacrylamide gels, stained with ethidium
bromide, and visualised under UV illumination. Each MSP was
repeated at least three times. We considered that the presence of a
visible PCR product in lane U or M indicated the presence of
unmethylated or methylated genes, respectively.
Reverse transcription (RT)–PCR
First strand cDNA was generated from RNA as described
previously (Hibi et al, 1991). The PCR amplification consisted of
30 cycles (951C for 30s, 551C for 1min, and 721C for 1min) after
the initial denaturation step (951C for 2min). The primers used
were CDH13-S (sense), 50-TTCAGCAGAAAGTGTTCCATAT, and
CDH13-AS (antisense), 50-GTGCATGGACGAACAGAGT. Primer
sequences were described previously (Sato et al, 1998). The
predicted size of the PCR product was 208bp. The housekeeping
gene, b-actin, was used as an internal control to confirm the
success of the RT reaction.
Statistical analysis
The w
2 test and Student
’s t-test were used to examine the
association between CDH13 promoter methylation and clinico-
pathological features.
RESULTS
We first examined the methylation status of CDH13 in colorectal
cancer cell lines (SW1083, SW1116, and SW1417) and an
oesophageal squamous cell cancer cell line (TE1) using MSP.
DNA from all colorectal cancer cell lines exhibited abnormal
promoter methylation of CDH13 gene (Figure 1). To confirm the
status of CDH13 gene according to the methylation pattern, we
next examined CDH13 expression in these cell lines using RT–
PCR. All colorectal cancer cell lines that demonstrated methylation
of the CDH13 promoter lacked CDH13 gene expression, while
CDH13 was expressed in the oesophageal cancer cell line with
unmethylation of the CDH13.
We next examined the methylation status of CDH13 promoter in
tumours using the MSP technique. Aberrant promoter methylation
of the CDH13 gene was detected in 27 of 84 (32%) colorectal
cancers. This result indicated that CDH13 aberrant methylation
might play an important role in colorectal cancers, as described
previously (Toyooka et al, 2002). According to the previous study,
49% of colorectal cancers that were collected from American
colorectal cancer patients showed CDH13 methylation. Colorectal
cancers that we examined were collected from Japanese colorectal
cancer patients. This might be the reason why there is a
discrepancy of the ratio of CDH13 methylation positivity between
the previous and our studies. A representative MSP analysis of
CDH13 gene promoter methylation from tumours is shown in
Figure 2. As a control, we screened the DNA of 84 corresponding
normal tissues for aberrant methylation, but found no methylation
of CDH13 in this group. Figure 2 showed no cases where
methylation of colorectal cancers was complete. Therefore, it
might be possible that the CDH13 gene expression has not been
inhibited completely in these cancers.
To determine the role of CDH13 inactivation in colorectal
cancer, we examined the correlation of methylation status with the
clinicopathological features. There was no significant difference in
the distribution of patients with positive or negative methylation of
CDH13 in terms of sex, maximal tumour size, the extent of tumour,
lymph node metastasis, or Dukes’ stage. However, we found a
significant difference in histology (P¼0.0053) when we compared
the CDH13 methylation of poorly differentiated colorectal cancers
to that of other differentiated ones (Table 1). These results suggest
that poorly differentiated colorectal cancers specifically exhibited
CDH13 methylation.
DISCUSSION
Colorectal cancer, one of the most aggressive cancers, occurs with
a high incidence in most countries (Greenlee et al, 2000). To rid
patients of this fatal cancer, tumours are resected and patients are
then treated with chemotherapy and radiotherapy. To eliminate
such cancers, it is also important to determine the genetic
alterations as a new parameter for an estimation of colorectal
cancer. Colorectal cancers are classified histopathologically as
either differentiated carcinomas forming tubular or papillary
structures or poorly differentiated carcinomas including mucinous
adenocarcinoma, in which such structures are inconspicuous.
Poorly differentiated colorectal carcinomas are quite rare,
comprising only 3–5% of all colorectal carcinomas. It is well
known that mucinous carcinoma is frequently observed in
colorectal cancer with genetic instability, but the difference in
genetic pathways between these histological types is mostly
unknown because of the very small number of cases (Risio et al,
1996).
In this study, we investigated the methylation status of CDH13 in
colorectal cancers and found that almost all (83%) poorly
differentiated colorectal cancers presented CDH13 methylation,
while only 28% of other differentiated colorectal cancers did.
CDH13, as a member of the cadherin family, would be a cell surface
glycoprotein responsible for cell adhesion. Therefore, it is
conceivable that CDH13 is inactivated in colorectal cancers by
promoter methylation, leading to cancer cell dissociation, which is
a characteristic of poorly differentiated carcinoma. Recently, it was
reported that most poorly differentiated colorectal carcinomas no
longer express E-cadherin, another cadherin family member,
SW1083
SW1083
SW1116
SW1116
SW1417
SW1417
TE1
TE1
dH2O
UM UMUMUM UM
CDH13
CDH13
methylation
status
expression
-Actin
Figure 1 Representative MSP of CDH13 promoter in colorectal cancer
cell lines (SW1083, SW1116, and SW1417) and oesophageal cancer cell
line (TE1). The presence of a visible PCR product in lane U indicates the
presence of unmethylated genes; the presence of PCR product in lane M
indicates the presence of methylated genes. All three colorectal cancer cell
lines that demonstrated only methylation of the CDH13 promoter lacked
CDH13 gene expression as determined by RT–PCR, while CDH13 was
expressed in TE1 with unmethylation of the CDH13 promoter.
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over, another study reported that the E-cadherin promoter
frequently underwent hypermethylation in human gastric cancers,
particularly those of the undifferentiated histologic subtype
(Tamura et al, 2000). These results support the notion that
the inactivation of cadherin family genes would be a critical
event in the scattering of carcinoma cells scattered because
they code for proteins responsible for selective cell recognition
and adhesion.
As described, the methylation of CDH13 gene would not be
complete, suggesting that the CDH13 gene expression has not
been inhibited completely in primary colorectal cancers. Zheng
et al (2001) reported previously that the partial methylation
pattern was associated with relatively low levels of p14ARF in
colorectal cancer cell lines. p14ARF mRNA was expressed at
extremely low levels in fully methylated cell lines. p14ARF
expression in the partial methylated LoVo cell line was inter-
mediate. Moreover, partial methylation of p14ARF was the
most common pattern observed in primary colorectal cancers.
Taken together, it was suggested that the level of CDH13 gene
expression might be also controlled by methylation in colorectal
cancers.
Recent studies have shown that it is possible to reverse
epigenetic changes and restore gene function to a cell. Treatment
with DNA methylation inhibitors can restore the activities of the
CDH13 gene and decrease the growth rate of cancer cells. The
administration of drugs such as cytosine analogues might soon
enable the functional restoration of these tumour suppressor genes
and slow the rate of colorectal cancer progression.
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Table 1 Clinicopathological features and methylation status of CDH13 promoter region in colorectal cancer patients
No. of cases
CDH13 methylation
Clinicopathological variable features +   P-value
Sex
Male 45 18 27 0.098
a
Female 39 9 30
Maximal tumour size
15–100mm 84 50.9721.3
b 45.2716.5 0.182
c
Histology
Poorly differentiated
d 6 5 1 0.0053
a
Other differentiated
e 78 22 56
Extent of tumour
%mt
f 20 6 14 0.814
a
mto 64 21 43
Lymph node metastasis
+ 31 6 25 0.055
a
  53 21 32
Dukes’ stage
A, B 54 19 35 0.423
a
C, D 30 8 22
Total 84 27 57
aw
2 test.
bMean7s.d.
cStudent
’s t-test.
dPoorly differentiated or mucinous adenocarcinoma according to Japanese criteria.
eWell- or moderately differentiated adenocarcinoma
according to Japanese criteria.
fMuscular tunic.
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